The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Fixed-duration teclistamab and talquetamab for frail patients with NDMM in FITFIX: trial-in-progress
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses the upcoming FITFIX study (NCT07107529), which will investigate fixed-duration teclistamab and talquetamab for frail patients with newly diagnosed multiple myeloma (NDMM). Dr Schjesvold highlights the potential benefits of this approach, including avoiding toxic treatments and the fixed duration of treatment with the option to restart upon progression. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, the FitFix study is interesting. It’s a frontline trial in the frail, exclusively in the frail patients. We’re giving them, we’re randomizing them between getting either teclistamab daratumumab or talquetamab daratumumab. So I think this is investigating immunotherapy in the frail patients, which are usually excluded from the other frontline bispecific trials or immunotherapy trials...
Yeah, the FitFix study is interesting. It’s a frontline trial in the frail, exclusively in the frail patients. We’re giving them, we’re randomizing them between getting either teclistamab daratumumab or talquetamab daratumumab. So I think this is investigating immunotherapy in the frail patients, which are usually excluded from the other frontline bispecific trials or immunotherapy trials. And I think there are some important things. I think the Majestic 3 data, which we’re seeing here, is showing how powerful the combination of daratumumab and teclistamab is. So I think that in these frail patients, to avoid lenalidomide and dexamethasone, which are quite toxic to frail patients, is really good. And I think the data we see here on the combination of TEC and DARA is also sort of, this study was made before we saw that data, but those data are strengthening this study. It shows that this is not sort of reduced just for the frail regimen it’s a regimen that’s really good and we are still giving it to the frail patient in this study and to avoid sort of long-term toxicity it’s also it’s a fixed duration so after 18 cycles you stop treatment then, and if they progress, you can restart the same treatment. So that’s also a good thing about the study. Most studies don’t have that, that you can restart after having stopped. So this will be exciting, of course. It’s a randomization between teclistamab and talquetamab with dara. That’s not a comparison, it’s just to show both regimens and not choose the treatment for each patient. It’s not meant to be compared, it’s a phase two trial. And I think we need these trials for the frail, because they are mostly excluded from other trials, to see the safety and to see the efficacy in these patients. So this is a trial in progress poster, not in the results. It hasn’t started yet, but it will start within some months now.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
